GlassScriptPhysician profile
Kazeem A Olajide
NPI 1184110165
$819.03
in general payments reported to CMS, 2019-2025
11 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $160 · 2022: $12.17 · 2023: $140 · 2024: $220 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $646.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $222.12 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $174.34 | 2021-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $137.89 | 2021-2025 | Austedo Xr, Austedo Xr |
| Gilead Sciences, INC. | $84.58 | 2024 | |
| Alkermes, INC. | $52.96 | 2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $42.09 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $36.71 | 2025 | Cobenfy |
| Lundbeck LLC | $26.40 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.96 | 2024 | Qelbree |
| Braeburn INC. | $14.73 | 2024 | Brixadi |
| Takeda Pharmaceuticals U.S.A., INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazeem Olajide listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.